PTI’s Final Call FiascoIntuitive Machines Stock Falls After Hours: Here's WhyInjuries are starting to take their toll on on fantasy rosters. Managers are being forced to hit the waiver wire and explore the depths of their bench in order to put together a lineup this week. Even if your team is missing some starters, a strong set of rankings will set you up for success on the fantasy gridiron. As you prepare for the 13th full Sunday of NFL football, we've got you covered with everything you need to set your fantasy football lineups. We have everything from positional rankings to sleepers and busts. Be sure to check back in often as our rankings will be updated regularly until kickoff on Sunday. WEEK 13 FANTASY ROSTER MANAGEMENT ADVICE Stock Watch | Start 'Em, Sit 'Em | Sleepers | Busts | Usage Report | Flex Finder | Weather Click section headers for additional positional analysis Week 13 Fantasy QB Rankings These rankings are for four-point passing TD leagues, and players who have already played are in italics. RANK PLAYER NAME TEAM OPPONENT CHANGE 1 Josh Allen BUF vs SF 2 Jalen Hurts PHI at BAL 3 Joe Burrow CIN vs PIT 4 Lamar Jackson BAL vs PHI 5 Justin Herbert LAC at ATL 6 Baker Mayfield TB at CAR 7 Jayden Daniels WAS vs TEN 8 Patrick Mahomes II KC vs LV 9 Matthew Stafford LAR at NO 10 Bo Nix DEN vs CLE 11 Tua Tagovailoa MIA at GB 12 Kyler Murray ARI at MIN 13 Brock Purdy SF at BUF N/R 14 C.J. Stroud HOU at JAC Down 1 15 Anthony Richardson IND at NE Down 1 16 Jordan Love GB vs MIA Down 1 17 Jared Goff DET vs CHI Down 1 18 Russell Wilson PIT at CIN Down 1 19 Drake Maye NE vs IND Down 1 20 Bryce Young CAR vs TB Down 1 21 Geno Smith SEA at NYJ Down 1 22 Sam Darnold MIN vs ARI Down 1 23 Kirk Cousins ATL vs LAC Down 1 24 Caleb Williams CHI at DET Down 1 25 Will Levis TEN at WAS Down 1 26 Derek Carr NO vs LAR Down 1 27 Jameis Winston CLE at DEN Down 1 28 Aaron Rodgers NYJ vs SEA Down 1 29 Cooper Rush DAL vs NYG Down 1 30 Aidan O'Connell LV at KC Down 1 31 Drew Lock NYG at DAL Down 1 32 Mac Jones JAC vs HOU Down 1 Week 13 Fantasy RB Rankings (PPR) Italicized players have already played this week. RANK PLAYER NAME TEAM OPPONENT CHANGE 1 Joe Mixon HOU at JAC 2 Saquon Barkley PHI at BAL 3 Josh Jacobs GB vs MIA Up 1 4 De'Von Achane MIA at GB Up 3 5 Bijan Robinson ATL vs LAC 6 Kyren Williams LAR at NO 7 Jahmyr Gibbs DET vs CHI Up 3 8 Alvin Kamara NO vs LAR Up 4 9 Jonathan Taylor IND at NE Down 1 10 Derrick Henry BAL vs PHI Up 3 11 James Cook BUF vs SF Up 3 12 Christian McCaffrey SF at BUF Down 1 13 Kenneth Walker Jr. SEA at NYJ Down 10 14 Breece Hall NYJ vs SEA Down 5 15 Tony Pollard TEN at WAS 16 David Montgomery DET vs CHI 17 Bucky Irving TB at CAR Up 1 18 Aaron Jones MIN vs ARI Up 1 19 Chuba Hubbard CAR vs TB Up 2 20 Tyrone Tracy Jr. NYG at DAL Down 3 21 Chase Brown CIN vs PIT Up 1 22 Rico Dowdle DAL vs NYG Up 2 23 Rhamondre Stevenson NE vs IND 24 Nick Chubb CLE at DEN Up 1 25 Isiah Pacheco KC vs LV N/R 26 James Conner ARI at MIN 27 D'Andre Swift CHI at DET 28 Najee Harris PIT at CIN Up 2 29 Rachaad White TB at CAR Up 2 30 Jaylen Warren PIT at CIN Up 2 31 Brian Robinson Jr. WAS vs TEN Down 3 32 Gus Edwards LAC at ATL Up 5 33 Kareem Hunt KC vs LV Down 13 34 Travis Etienne Jr. JAC vs HOU Down 1 35 Javonte Williams DEN vs CLE Down 1 36 Tank Bigsby JAC vs HOU Down 1 37 Tyler Allgeier ATL vs LAC Down 1 38 Roschon Johnson CHI at DET 39 Jeremy McNichols WAS vs TEN Up 1 40 Braelon Allen NYJ vs SEA Down 1 41 Ameer Abdullah LV at KC Down 1 42 Hassan Haskins LAC at ATL N/R 43 Cam Akers MIN vs ARI Down 1 44 Trey Benson ARI at MIN Down 1 45 Antonio Gibson NE vs IND Down 1 46 Justice Hill BAL vs PHI N/R 47 Zach Charbonnet SEA at NYJ Down 2 48 Jerome Ford CLE at DEN Down 2 49 Blake Corum LAR at NO Down 2 50 Audric Estime DEN vs CLE Down 2 51 Ray Davis BUF vs SF Down 2 52 Devin Singletary NYG at DAL Down 2 53 Kenneth Gainwell PHI at BAL Down 2 54 Jonathon Brooks CAR vs TB Down 2 55 Kimani Vidal LAC at ATL N/R 56 D'Ernest Johnson JAC vs HOU Down 1 57 Emanuel Wilson GB vs MIA Down 1 58 Khalil Herbert CIN vs PIT Down 1 59 Emari Demercado ARI at MIN Down 1 60 Jaleel McLaughlin DEN vs CLE Down 1 61 Jaylen Wright MIA at GB Down 1 62 Sean Tucker TB at CAR Down 1 63 Ty Johnson BUF vs SF Down 1 64 Jordan Mason SF at BUF Down 1 65 Chris Rodriguez Jr. WAS vs TEN N/R 66 Dylan Laube LV at KC Down 2 67 Samaje Perine KC vs LV Down 2 68 Cordarrelle Patterson PIT at CIN Down 2 69 Trey Sermon IND at NE Down 2 70 Trayveon Williams CIN vs PIT Down 2 71 Raheem Mostert MIA at GB Down 2 72 Ezekiel Elliott DAL vs NYG Down 2 73 Dameon Pierce HOU at JAC Down 2 74 Ty Chandler MIN vs ARI Down 2 75 Pierre Strong Jr. CLE at DEN Down 2 76 Hunter Leupke DAL vs NYG Down 2 Week 13 Fantasy WR Rankings (PPR) Italicized players have already played this week. RANK PLAYER NAME TEAM OPPONENT CHANGE 1 A.J. Brown PHI at BAL 2 Nico Collins HOU at JAC 3 Ja'Marr Chase CIN vs PIT 4 Justin Jefferson MIN vs ARI 5 Puka Nacua LAR at NO 6 Mike Evans TB at CAR 7 CeeDee Lamb DAL vs NYG 8 Amon-Ra St. Brown DET vs CHI 9 Cooper Kupp LAR at NO 10 Calvin Ridley TEN at WAS 11 Tyreek Hill MIA at GB 12 George Pickens PIT at CIN 13 Courtland Sutton DEN vs CLE 14 Drake London ATL vs LAC 15 Ladd McConkey LAC at ATL 16 Garrett Wilson NYJ vs SEA 17 Terry McLaurin WAS vs TEN 18 Brian Thomas Jr. JAC vs HOU 19 Jaxon Smith-Njigba SEA at NYJ 20 Tee Higgins CIN vs PIT 21 Jaylen Waddle MIA at GB 22 DK Metcalf SEA at NYJ 23 Jayden Reed GB vs MIA 24 Malik Nabers NYG at DAL 25 Zay Flowers BAL vs PHI Up 1 26 Khalil Shakir BUF vs SF Up 1 27 DJ Moore CHI at DET Up 1 28 DeAndre Hopkins KC vs LV Up 1 29 Jauan Jennings SF at BUF Up 1 30 Tank Dell HOU at JAC Up 1 31 Marvin Harrison Jr. ARI at MIN Up 1 32 Michael Pittman Jr. IND at NE N/R 33 Jordan Addison MIN vs ARI 34 Xavier Legette CAR vs TB 35 Keenan Allen CHI at DET 36 Jakobi Meyers LV at KC 37 Darnell Mooney ATL vs LAC Up 3 38 Amari Cooper BUF vs SF Doown 1 39 Nick Westbrook-Ikhine TEN at WAS Down 1 40 Devaughn Vele DEN vs CLE Down 1 41 DeMario Douglas NE vs IND 42 Quentin Johnston LAC at ATL Down 7 43 Jerry Jeudy CLE at DEN Down 1 44 Jameson Williams DET vs CHI Down 1 45 Deebo Samuel Sr. SF at BUF Down 1 46 Marquez Valdes-Scantling NO vs LAR 47 Christian Watson GB vs MIA Down 1 48 Davante Adams NYJ vs SEA Down 1 49 Xavier Worthy KC vs LV Down 1 50 Adam Thielen CAR vs TB Down 1 51 Wan'Dale Robinson NYG at DAL Down 1 52 Rome Odunze CHI at DET Down 1 53 Kendrick Bourne NE vs IND Down 1 54 Dontayvion Wicks GB vs MIA Down 1 55 Alec Pierce IND at NE Down 1 56 Rashod Bateman BAL vs PHI Down 1 57 Jalen Tolbert DAL vs NYG Down 1 58 Jalen McMillan TB at CAR Down 1 59 Noah Brown WAS vs TEN Down 1 60 David Moore CAR vs TB Down 1 61 Jalen Nailor MIN vs ARI Down 1 62 Michael Wilson ARI at MIN Down 1 63 Curtis Samuel BUF vs SF Down 1 64 Joshua Palmer LAC at ATL Down 1 65 Elijah Moore CLE at DEN Down 1 66 John Metchie HOU at JAC Down 1 67 Calvin Austin PIT at CIN Down 1 68 Kayshon Boutte NE vs IND Down 1 69 Lil'Jordan Humphrey DEN vs CLE Down 1 70 Tyler Lockett SEA at NYJ Down 1 71 Ray-Ray McCloud ATL vs LAC Down 1 72 Demarcus Robinson LAR at NO Down 1 73 Mike Williams PIT at CIN Down 1 74 Tyler Boyd TEN at WAS Down 1 75 KaVonte Turpin DAL vs NYG Down 1 76 Sterling Shepard TB at CAR Down 1 77 Darius Slayton NYG at DAL Down 1 78 Ricky Pearsall SF at BUF Down 1 79 Adonai Mitchell IND at NE Down 1 80 DJ Turner LV at KC Down 1 81 Parker Washington JAC vs HOU Down 1 82 Mack Hollins BUF vs SF Down 1 83 Olamide Zaccheaus WAS vs TEN Down 1 84 Marvin Mims Jr. DEN vs CLE Down 1 85 Tre Tucker LV at KC Down 1 86 Troy Franklin DEN vs CLE Down 1 87 Juju Smith-Schuster KC vs LV Down 1 88 Jahan Dotson PHI at BAL Down 1 89 Devin Duvernay JAC vs HOU Down 1 90 Justin Watson KC vs LV Down 1 91 Andrei Iosivas CIN vs PIT Down 1 92 Tutu Atwell LAR at NO Down 1 93 Zay Jones ARI at MIN Down 1 94 Jermaine Burton CIN vs PIT Down 1 95 Mason Tipton NO vs LAR Down 1 96 Malik Washington MIA at GB Down 1 97 Diontae Johnson BAL vs PHI Down 1 98 Malachi Corley NYJ vs SEA Down 1 Week 13 Fantasy Rankings TE (PPR) Italicized players have already played this week. RANK PLAYER NAME TEAM OPPONENT CHANGE 1 Travis Kelce KC vs LV 2 Brock Bowers LV at KC 3 Trey McBride ARI at MIN 4 George Kittle SF at BUF 5 Cade Otton TB at CAR 6 Dallas Goedert PHI at BAL 7 T.J. Hockenson MIN vs ARI 8 Jonnu Smith MIA at GB 9 Evan Engram JAC vs HOU 10 Hunter Henry NE vs IND 11 Will Dissly LAC at ATL 12 Taysom Hill NO vs LAR 13 Pat Freiermuth PIT at CIN 14 David Njoku CLE at DEN 15 Kyle Pitts ATL vs LAC 16 Zach Ertz WAS vs TEN 17 Dawson Knox BUF vs SF 18 Dalton Schultz HOU at JAC 19 Sam LaPorta DET vs CHI 20 Tucker Kraft GB vs MIA 21 Mark Andrews BAL vs PHI 22 Luke Schoonmaker DAL vs NYG 23 Noah Fant SEA at NYJ N/R 24 Cole Kmet CHI at DET Down 1 25 Noah Gray KC vs LV Down 1 26 Juwan Johnson NO vs LAR Down 1 27 Mike Gesicki CIN vs PIT Down 1 28 Theo Johnson NYG at DAL Down 1 29 Tyler Conklin NYJ vs SEA Down 1 30 Austin Hooper NE vs IND Down 1 31 Adam Trautman DEN vs CLE Down 1 32 Chigoziem Okonkwo TEN at WAS Down 1 33 Isaiah Likely BAL vs PHI Down 1 34 Darnell Washington PIT at CIN Down 1 35 Davis Allen LAR at NO Down 1 36 Michael Mayer LV at KC Down 1 37 Foster Moreau NO vs LAR Down 1 38 Colby Parkinson LAR at NO Down 1 39 Tanner Hudson CIN vs PIT Down 1 40 Mo Alie-Cox IND at NE Down 1 41 Lucas Krull DEN vs CLE Down 1 42 Grant Calcaterra PHI at BAL Down 1 43 Brenton Strange JAC vs HOU Down 1 44 Josh Oliver MIN vs ARI Down 1 45 Kylen Granson IND at NE Down 1 46 Ben Sinnott WAS vs TEN Down 1 47 Elijah Higgins ARI at MIN Down 1 48 Gerald Everett CHI at DET Down 1 Week 13 Fantasy Defense Rankings Italicized teams have already played this week. RANK TEAM OPPONENT CHANGE 1 Denver Broncos vs CLE 2 Kansas City Chiefs vs LV 3 Washington Commanders vs TEN 4 Los Angeles Chargers at ATL 5 Tampa Bay Buccaneers at CAR 6 Houston Texans at JAC 7 Seattle Seahawks at NYJ Up 2 8 Buffalo Bills vs SF 9 Cleveland Browns at DEN Down 2 10 Minnesota Vikings vs ARI Up 3 11 Detroit Lions vs CHI 12 Pittsburgh Steelers at CIN 13 Green Bay Packers vs MIA Up 9 14 Arizona Cardinals at MIN Down 4 15 Philadelphia Eagles at BAL 16 Los Angeles Rams at NO 17 New York Jets vs SEA 18 Miami Dolphins at GB Down 4 19 Tennessee Titans at WAS Up 6 20 Indianapolis Colts at NE Down 2 21 Dallas Cowboys vs NYG 22 Chicago Bears at DET Up 6 23 New York Giants at DAL Down 4 24 San Francisco 49ers at BUF 25 Baltimore Ravens vs PHI Up 1 26 New England Patriots vs IND Down 6 27 New Orleans Saints vs LAR Down 4 28 Las Vegas Raiders at KC Down 1 29 Atlanta Falcons vs LAC 30 Cincinnati Bengals vs PIT 31 Jacksonville Jaguars vs HOU 32 Carolina Panthers vs TB Week 13 Fantasy Kicker Rankings Italicized teams have already played this week. RANK PLAYER TEAM OPPONENT CHANGE 1 Chris Boswell PIT at CIN 2 Cameron Dicker LAC at ATL 3 Ka'imi Fairbairn HOU at JAC 4 Jake Bates DET vs CHI 5 Chase McLaughlin TB at CAR 6 Brandon Aubrey DAL vs NYG 7 Younghoe Koo ATL vs LAC 8 Tyler Bass BUF vs SF 9 Joshua Karty LAR at NO 10 Justin Tucker BAL vs PHI 11 Jake Moody SF at BUF 12 Brandon McManus GB vs MIA 13 Jason Myers SEA at NYJ 14 Chad Ryland ARI at MIN 15 Jason Sanders MIA at GB 16 Jake Elliott PHI at BAL 17 Zane Gonzalez WAS vs TEN 18 Graham Gano NYG at DAL 19 Evan McPherson CIN vs PIT 20 Spencer Shrader KC vs LV 21 Matt Gay IND at NE 22 Wil Lutz DEN vs CLE 23 Daniel Carlson LV at KC 24 Cairo Santos CHI at DET 25 Blake Grupe NO vs LAR 26 Anders Carlson NYJ vs SEA 27 John Parker Romo MIN vs ARI 28 Dustin Hopkins CLE at DEN 29 Nick Folk TEN at WAS 30 Joey Slye NE vs IND 31 Cam Little JAC vs HOU 32 Eddy Pineiro CAR vs TB
This year, Kim Stark’s kids took responsibility for decorating the family Christmas tree. Ornaments include toy cars, puzzle pieces, string and a pair of binoculars — things her three young daughters had handy after the family lost their home in summer’s devastating Jasper wildfire. “I have the most wonderful tree on the planet,” said Stark. “It’s part of our story and part of who we are. “If (the kids) are happy, I’m happy.” Stark is part of the fabric of the Jasper townsite, a 10-year member of the fire department and owner of a coffee shop and bakery. Her family, plus three furry pets and a fish, are living in a condo as they navigate rebuilding their home. “(The kids) miss our house, and we talk about our house,” said Stark. “We make sure we go to our neighbourhood, so that it doesn’t become somebody else’s neighbourhood.” Stark and other residents are anxious and nervous for the future following the fire that hit the town July 24. About 5,000 residents and 20,000 visitors were safely evacuated before the fire breached the western edge of town and destroyed 350 homes and businesses, including 820 housings units. The Insurance Bureau of Canada pegged the damage at $880 million. Six months after the fire, debris is still being cleared — lot by lot. Locals including Stark are quick to say things could have been worse. But anxiety over temporary living situations and what may be a long and slow rebuild process has many residents and municipal leaders feeling unsettled heading into 2025. For Sabrina Charlebois and David Leoni, the top concern is the Alberta government’s $112-million modular housing project. It’s to put up 250 pre-built rental units in the town and rent them to those displaced by the fire. Social Services Minister Jason Nixon said the first homes should be ready by late January or early February, with the rest in April. The majority are to be multi-bedroom suites to accommodate families. “If we can get all of our approvals on time, we definitely are on time to be able to build in the context of what we promised,” Nixon said. It’s complicated, he added, given there are layers of government with an Alberta town in a national park. Charlebois was born and raised in Jasper. The fire destroyed her childhood home, which her late father built, as well as the salon where she worked. “It’s better than nothing,” she said of the housing project, noting at least 2,000 residents were displaced so demand could outnumber the new units. Charlebois, who has been staying in a hotel, said it’s understandable projects like this take time. But “we’re six months into this, and there’s no homes for anyone.” “My fear is not finding a place to live, because I have to be out of my hotel by the spring,” she said. Leoni, a dentist and former Olympic biathlete, and his family also lost their home, as did seven staff at his clinic. He said the April cutoff date Charlebois is facing also applies to his staff staying in hotels. “Hopefully that’s concurrent with the provincial government’s opening of these modular units that they’re putting in, because we’re going to lose staff,” said Leoni. “Without them I can’t do anything.” The clinic needed to replace $160,000 worth of equipment and required a top-to-bottom scrub before appointments resumed in October. Leoni estimates his patient list is down one-third because of the fire. Whether those patients return remains to be seen. Charlebois and Leoni both said their anxiety is heightened when they consider the unpredictable nature of the town’s tourism economy and how it could complicate the pace of rebuilding. It’s a catch-22: residents need houses in order to rebuild and restart the economy, but they can’t restart the economy without tourists. And tourists require services, which require workers, who require housing. Bill Given, the town’s chief administrator, said he’s optimistic the municipality can “thread the needle.” But he has his own anxieties when it comes to rebuilding, namely the complexity of Jasper operating under both federal and provincial oversight. “An associated risk of that is that individual agendas from different orders of government overtake the public interest in delivering on what Jasper needs,” Given said. “I think there’s also a risk, maybe somewhat smaller, that private interests overtake the broader public interest.” Jasper Mayor Richard Ireland, who lost his home in the fire, said they have to find a way. “Failure is not an option for anybody,” said Ireland. “We have one chance to get this right, and that’s what we have to do.” In the meantime, Stark and her daughters watch from behind a fence as what’s left of their home is cleared away. “I’m super excited just to have a hole instead of a burnt spiral staircase that was coming up in my backyard. “Now,” she said, “it’s just this beautiful dirt. “There’s future there.” Jack Farrell, The Canadian Press
Aaron Rodgers Fights Back From Injury, Buddies Up With RFK Jr. in Trailer for Netflix Doc Enigma — Watch - TVLine
NoneLAS VEGAS — A rap icon is in the theater and, yes, in the club over New Year’s Eve. “50 Cent: In Da Club” runs Friday through Jan. 4 at PH Live, the former Bakkt Theater and (going to its origins) Aladdin Theatre for the Performing Arts. This is a custom-designed, Las Vegas-peppered production, a first for the rapper born Curtis James Jackson III. As the series opens, 50 Cent and Eminem generated international buzz by teasing to a joint album. “Looks like I’ll be back in the booth after all! Just gotta do this residency in Vegas first,” 50 posted on social media Friday morning. Eminem said in an interview on DJ Whoo Kidd’s “Whoo’s House” on SiriusXM’s Shade 45 this week he would be interested in such a collaboration. “That would be great,” Eminem said. “We just gotta stop (B.S.-ing) and just do it ... “I would never say it’s not possible.” This month Snoop Dogg and Dr. Dre invited the two superstars to guest on their “Missionary” release. They teamed on “Gunz N Smoke.” Over the years, 50 and Eminem have also collaborated on “Patiently Waiting,” “Crack a Bottle,” “Don’t Push Me” and many more. Until the two reconvene, there is the matter of 50 Cent’s half-dozen performances at PH Live. Asked how the shows on the Strip will be Vegas-centric, 50 said, “I have never done a Vegas residency before so this will be my first time doing consecutive shows on a stationary stage and this will enable me to bring many new elements of production and really turn it up for the audience. “ As for his history of New Year’s Eve performances, or NYE generally, the rapper said, “My favorite NYE memory is all of them because I use it as a reset to set my goal for the new year, and I am raising my bar every time and my favorite place to be on NYE is on a stage performing for everyone.” ©2024 Las Vegas Review-Journal. Visit reviewjournal.com. . Distributed by Tribune Content Agency, LLC.NEW YORK (AP) — Yankees slugger Aaron Judge wins his second AL MVP award after leading MLB with 58 home runs.
CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $
Arkansas DE Landon Jackson carted off field and taken to hospital with neck injuryCitius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update